Private Wealth Advisors LLC Purchases 134,198 Shares of Delcath Systems, Inc. $DCTH

Private Wealth Advisors LLC grew its position in shares of Delcath Systems, Inc. (NASDAQ:DCTH) by 85.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 290,481 shares of the company’s stock after acquiring an additional 134,198 shares during the quarter. Private Wealth Advisors LLC’s holdings in Delcath Systems were worth $2,934,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of DCTH. Nantahala Capital Management LLC bought a new stake in shares of Delcath Systems during the third quarter valued at approximately $7,164,000. Marshall Wace LLP bought a new stake in shares of Delcath Systems during the second quarter valued at approximately $6,572,000. Divisadero Street Capital Management LP bought a new stake in shares of Delcath Systems during the third quarter valued at approximately $5,119,000. Rosalind Advisors Inc. increased its holdings in shares of Delcath Systems by 13.8% during the second quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company’s stock valued at $44,885,000 after acquiring an additional 400,000 shares in the last quarter. Finally, Propel Bio Management LLC increased its holdings in shares of Delcath Systems by 94.0% during the third quarter. Propel Bio Management LLC now owns 438,509 shares of the company’s stock valued at $4,714,000 after acquiring an additional 212,457 shares in the last quarter. Institutional investors own 61.12% of the company’s stock.

Delcath Systems Price Performance

Shares of NASDAQ:DCTH opened at $11.23 on Thursday. The company has a market capitalization of $387.66 million, a PE ratio of 1,123.00 and a beta of 0.54. The business has a fifty day moving average price of $10.24 and a two-hundred day moving average price of $9.87. Delcath Systems, Inc. has a 1 year low of $8.12 and a 1 year high of $18.19.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.07. The firm had revenue of $24.99 million during the quarter, compared to the consensus estimate of $23.51 million. Delcath Systems had a return on equity of 0.51% and a net margin of 0.62%. Sell-side analysts anticipate that Delcath Systems, Inc. will post -0.88 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. BTIG Research decreased their price target on Delcath Systems from $23.00 to $19.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Evercore set a $27.00 price target on Delcath Systems in a report on Thursday, February 26th. Zacks Research downgraded Delcath Systems from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. Weiss Ratings upgraded Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Finally, Wall Street Zen downgraded Delcath Systems from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Five research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Delcath Systems presently has a consensus rating of “Hold” and an average price target of $22.50.

Delcath Systems Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.